METHYLDOPA tablet Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

methyldopa tablet

mylan pharmaceuticals inc. - methyldopa (unii: 56lh93261y) (methyldopa anhydrous - unii:m4r0h12f6m) - methyldopa anhydrous 250 mg - hypertension. methyldopa is contraindicated in patients:

METHYLDOPA tablet Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

methyldopa tablet

mylan institutional inc. - methyldopa (unii: 56lh93261y) (methyldopa anhydrous - unii:m4r0h12f6m) - methyldopa anhydrous 500 mg - hypertension. methyldopa is contraindicated in patients: - with active hepatic disease, such as acute hepatitis and active cirrhosis. - with liver disorders previously associated with methyldopa therapy (see warnings). - with hypersensitivity to any component of this product. - on therapy with monoamine oxidase (mao) inhibitors.

METHYLDOPA tablet, film coated Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

methyldopa tablet, film coated

rebel distributors corp - methyldopa (unii: 56lh93261y) (methyldopa anhydrous - unii:m4r0h12f6m) - methyldopa anhydrous 250 mg - hypertension. methyldopa is contraindicated in patients: - with active hepatic disease, such as acute hepatitis and active cirrhosis. - with liver disorders previously associated with methyldopa therapy (see warnings ). - with hypersensitivity to any component of this product. - on therapy with monoamine oxidase (mao) inhibitors.

METHYLDOPA tablet, film coated Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

methyldopa tablet, film coated

physicians total care, inc. - methyldopa (unii: 56lh93261y) (methyldopa - unii:56lh93261y) - methyldopa 250 mg - hypertension. methyldopa is contraindicated in patients: - with active hepatic disease, such as acute hepatitis and active cirrhosis. - with liver disorders previously associated with methyldopa therapy (see warnings ). - with hypersensitivity to any component of this product. - on therapy with monoamine oxidase (mao) inhibitors.

METHYLDOPA AND HYDROCHLOROTHIAZIDE tablet Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

methyldopa and hydrochlorothiazide tablet

mylan pharmaceuticals inc. - methyldopa (unii: 56lh93261y) (methyldopa anhydrous - unii:m4r0h12f6m), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - methyldopa anhydrous 250 mg - hypertension - (see box warning). methyldopa and hydrochlorothiazide tablets are contraindicated in patients:

TRIDOPA levodopa/carbidopa/entacapone 150/37.5/200 mg tablet bottle Australien - Englisch - Department of Health (Therapeutic Goods Administration)

tridopa levodopa/carbidopa/entacapone 150/37.5/200 mg tablet bottle

stada pharmaceuticals australia pty ltd - carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg; levodopa, quantity: 150 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; hyprolose; magnesium stearate; microcrystalline cellulose; sodium sulfate; carmellose sodium; powdered cellulose; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

TRIDOPA levodopa/carbidopa/entacapone 125/31.25/200 mg tablet bottle Australien - Englisch - Department of Health (Therapeutic Goods Administration)

tridopa levodopa/carbidopa/entacapone 125/31.25/200 mg tablet bottle

stada pharmaceuticals australia pty ltd - carbidopa monohydrate, quantity: 33.75 mg (equivalent: carbidopa, qty 31.25 mg); entacapone, quantity: 200 mg; levodopa, quantity: 125 mg - tablet, film coated - excipient ingredients: magnesium stearate; powdered cellulose; sodium sulfate; hyprolose; microcrystalline cellulose; trehalose dihydrate; carmellose sodium; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

TRIDOPA levodopa/carbidopa/entacapone 75/18.75/200 mg tablet bottle Australien - Englisch - Department of Health (Therapeutic Goods Administration)

tridopa levodopa/carbidopa/entacapone 75/18.75/200 mg tablet bottle

stada pharmaceuticals australia pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; microcrystalline cellulose; carmellose sodium; hyprolose; sodium sulfate; magnesium stearate; powdered cellulose; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

CARBIDOPA AND LEVODOPA tablet, extended release Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

carbidopa and levodopa tablet, extended release

ncs healthcare of ky, inc dba vangard labs - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 25 mg - indications and usage: carbidopa and levodopa extended-release tablets are indicated in the treatment of parkinson's disease, postencephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. contraindications: nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa extended-release tablets. these inhibitors must be discontinued at least 2 weeks prior to initiating therapy with carbidopa and levodopa extended-release. carbidopa and levodopa extended-release may be administered concomitantly with the manufacturer's recommended dose of an mao inhibitor with selectivity for mao type b (e.g., selegiline hydrochloride) (see precautions: drug interactions ).     carbidopa and levodopa extended-release is contraindicated in patients with known hypersensitivity to any component of this drug and in patients with narrow-angle glaucoma.

DOPAMINE HYDROCHLORIDE S.A.L.F. 40 MG1 ML Israel - Englisch - Ministry of Health

dopamine hydrochloride s.a.l.f. 40 mg1 ml

raz pharmaceutics ltd, israel - dopamine hydrochloride - concentrate for solution for infusion - dopamine hydrochloride 40 mg / 1 ml - dopamine - dopamine hydrochloride s.a.l.f. is used for the treatment of states of shock of different nature:- post myocardial infarction cardiogenic shock, a shock caused by a heart attack,- surgical shock, caused by a surgical operation,- hypovolemic or haemorrhagic shock, caused by a decrease in blood volume due to a hemorrhage,a shock is characterized by a sharp decrease in blood pressure in response to a reduced blood flow in the organism.